Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.

Period	Debt/Equity
2020-12-31	0.03
2021-12-31	1.24
2022-12-31	132.06
2023-12-31	1.31
2024-12-31	1.24

	A	B	C	D
1	Symbol	Price	Change	Volume
2	TSHA	$4.54	-0.55%	0.95M
3
4
5

Taysha Gene Therapies Inc. (TSHA) Debt to Equity Ratio

Debt to Equity Ratio Data

Get Taysha Gene Therapies Inc. Data in Excel

More TSHA Financial Data